We have developed a novel treatment for Rheumatoid Arthritis (RA), which prevents the onset or exacerbation of the disease.For the development of this novel therapy, we focussed on more RA specific targets like Deiminated Peptide-Epitopes (DPE).Deimination is the posttranslational modification of arginine into citrulline residues induced by peptidylarginine deiminases that are released in the inflamed joints from dying cells.A growing number of studies indicated that these modifications could be responsible for the initial triggering of autoimmunity and the breaking of tolerance.